The role of ATP-binding cassette transporter genes in the progression of prostate cancer

Prostate

Volumn 76, Issue 5, 2016, Pages 434-444

  Karatas, Omer F ^a   Guzel, Esra ^b,c   Ittmann, Michael ^d,e   Ozen, Mustafa ^b,c,d  

^a ERZURUM TECHNICAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c BIRUNI UNIVERSITY   (Turkey)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ABC transporters; prognosis; progression; prostate cancer; recurrence

Indexed keywords

ABC TRANSPORTER; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 5;

ABCA5 GENE; ABCB1 GENE; ABCB6 GENE; ABCC1 GENE; ABCC10 GENE; ABCC2 GENE; ABCC3 GENE; ABCC5 GENE; ABCF2 GENE; ADULT; ARTICLE; ATP BINDING CASSETTE TRANSPORTER GENE; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

ATP-BINDING CASSETTE TRANSPORTERS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84958759707     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23137     Document Type: Article

References (48)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64 (1): 9-29.
2. Quinn M, Babb P,. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: International comparisons. BJU Int 2002; 90 (2): 162-173.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
4. Adamis S, Varkarakis IM,. Defining prostate cancer risk after radical prostatectomy. Eur J Surg Oncol 2014; 40 (5): 496-504.
5. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH,. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169 (4): 1320-1324.
6. Cannistraci A, Di Pace AL, De Maria R, Bonci D,. MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: Results from clinical data set and patients' samples. Biomed Res Int 2014; 2014: 146170.
7. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-523.
8. Guzel E, Karatas OF, Duz MB, Solak M, Ittmann M, Ozen M,. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. Prostate 2014; 74 (15): 1498-1505.
9. Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, Ittmann M, Ozen M,. MiR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS ONE 2014; 9 (6): e98675.
10. Hlavac V, Brynychova V, Vaclavikova R, Ehrlichova M, Vrana D, Pecha V, Kozevnikovova R, Trnkova M, Gatek J, Kopperova D, Gut I, Soucek P,. The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics 2013; 14 (5): 515-529.
11. Dean M,. The genetics of ATP-binding cassette transporters. Methods Enzymol 2005; 400: 409-429.
12. Morita M, Imanaka T,. Peroxisomal ABC transporters: Structure, function and role in disease. Biochim Biophys Acta 2012; 1822 (9): 1387-1396.
13. Fletcher JI, Haber M, Henderson MJ, Norris MD,. ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer 2010; 10 (2): 147-156.
14. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B,. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011; 2011: 941876.
15. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD,. ABCC multidrug transporters in childhood neuroblastoma: Clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011; 103 (16): 1236-1251.
16. Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ,. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst 2014; 106 (7): dju149.
17. Pavlidis P, Noble WS,. Matrix2png: A utility for visualizing matrix data. Bioinformatics 2003; 19 (2): 295-296.
18. Sun Y, Goodison S,. Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 2009; 69 (10): 1119-1127.
19. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA,. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.
20. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH,. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22 (14): 2790-2799.
21. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka P, Soucek P,. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2012; 27 (2): 187-196.
22. Tsuda H, Ito K, Yaegashi N, Hirasawa A, Sudo T, Kita T, Terai Y, Kigawa J, Sugiyama T, Aoki D,. Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer 2010; 20 (5): 794-797.
23. Polireddy K, Chavan H, Abdulkarim BA, Krishnamurthy P,. Functional significance of the ATP-binding cassette transporter B6 in hepatocellular carcinoma. Mol Oncol 2011; 5 (5): 410-425.
24. Tsunedomi R, Iizuka N, Yoshimura K, Iida M, Tsutsui M, Hashimoto N, Kanekiyo S, Sakamoto K, Tamesa T, Oka M,. ABCB6 mRNA and DNA methylation levels serve as useful biomarkers for prediction of early intrahepatic recurrence of hepatitis C virus-related hepatocellular carcinoma. Int J Oncol 2013; 42 (5): 1551-1559.
25. Zhao SG, Chen XF, Wang LG, Yang G, Han DY, Teng L, Yang MC, Wang DY, Shi C, Liu YH, Zheng BJ, Shi CB, Gao X, Rainov NG,. Increased expression of ABCB6 enhances protoporphyrin IX accumulation and photodynamic effect in human glioma. Ann Surg Oncol 2013; 20 (13): 4379-4388.
26. Barbet R, Peiffer I, Hutchins JR, Hatzfeld A, Garrido E, Hatzfeld JA,. Expression of the 49 human ATP binding cassette (ABC) genes in pluripotent embryonic stem cells and in early- and late-stage multipotent mesenchymal stem cells: Possible role of ABC plasma membrane transporters in maintaining human stem cell pluripotency. Cell Cycle 2012; 11 (8): 1611-1620.
27. Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova E, Kala Z, Muckova K, Soucek P,. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Pancreas 2013; 42 (4): 707-716.
28. Domanitskaya N, Wangari-Talbot J, Jacobs J, Peiffer E, Mahdaviyeh Y, Paulose C, Malofeeva E, Foster K, Cai KQ, Zhou Y, Egleston B, Hopper-Borge E,. Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response. Br J Cancer 2014; 111 (4): 696-707.
29. Borel F, Han R, Visser A, Petry H, van Deventer SJ, Jansen PL, Konstantinova P,. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012; 55 (3): 821-832.
30. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC,. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 2013; 12 (9): 1829-1836.
31. Zhang W, Shannon WD, Duncan J, Scheffer GL, Scheper RJ, McLeod HL,. Expression of drug pathway proteins is independent of tumour type. J Pathol 2006; 209 (2): 213-219.
32. Li DW, Gao S, Shen B, Dong P,. Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma. Med Oncol 2011; 28 (Suppl 1): S333-S340.
33. Henrique R, Oliveira AI, Costa VL, Baptista T, Martins AT, Morais A, Oliveira J, Jeronimo C,. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. BMC Genomics 2013; 14: 898.
34. Ohtsuki S, Kamoi M, Watanabe Y, Suzuki H, Hori S, Terasaki T,. Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull 2007; 30 (6): 1144-1146.
35. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Putzer BM,. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11 (16): 3067-3078.
36. Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH,. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS ONE 2012; 7 (8): e41401.
37. Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, Muwakkit SA,. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2014; 24 (8): 387-396.
38. Ma CL, Wu XY, Zheng J, Wu ZY, Hong Z, Zhong MK,. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics 2014; 15 (10): 1323-1336.
39. Chen KG, Valencia JC, Gillet JP, Hearing VJ, Gottesman MM,. Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res 2009; 22 (6): 740-749.
40. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Takamura M, Yano M, Sanpei A, Aoyagi Y, Hatakeyama K, Ajioka Y,. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 2010; 23 (4): 965-972.
41. Sandusky GE, Mintze KS, Pratt SE, Dantzig AH,. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 2002; 41 (1): 65-74.
42. Liu C, Li Z, Bi L, Li K, Zhou B, Xu C, Huang J, Xu K,. NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells. Mol Cell Biochem 2014; 393 (1-2): 265-270.
43. Munoz M, Henderson M, Haber M, Norris M,. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007; 59 (12): 752-757.
44. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, Chang TH, Weng SL, Liao KW, Liao IE, Liu CC, Huang HD,. MiRTarBase update 2014: An information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res 2014; 42 (Database issue): D78-D85.
45. Dweep H, Sticht C, Pandey P, Gretz N,. MiRWalk-database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011; 44 (5): 839-847.
46. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
47. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101 (3): 811-816.
48. Kurdistani SK,. Histone modifications as markers of cancer prognosis: A cellular view. Br J Cancer 2007; 97 (1): 1-5.